Evidence map›Paper›PMID 29234055›Full record

Trial reportScientific reports2017

Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial.

Masaya Takahashi, Kazuhiko Soejima, Shoichiro Taniuchi, Yasuko Hatano, Sohsaku Yamanouchi, Hideki Ishikawa, Makoto Irahara, Youhei Sasaki, Hiroshi Kido, Kazunari Kaneko

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. GAClinical and translational allergy · 2024
    Review
  17. Review
  18. Review
  19. Review
  20. Oral Immunotherapy in Food Allergy: Where Are We Now?Allergy, asthma & immunology research · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Masaya TakahashiDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan.
Kazuhiko SoejimaDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan.
Shoichiro TaniuchiDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan. taniuchishoichiro@gmail.com.
Yasuko HatanoDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan.
Sohsaku YamanouchiDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan.
Hideki IshikawaDepartment of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.
Makoto IraharaDepartment of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, 770-8501, Japan.
Youhei SasakiDivision of Enzyme Chemistry, Institute for Enzyme Research, Tokushima University, Tokushima, 770-8501, Japan.
Hiroshi KidoDivision of Enzyme Chemistry, Institute for Enzyme Research, Tokushima University, Tokushima, 770-8501, Japan.
Kazunari KanekoDepartment of Pediatrics, Kansai Medical University, Osaka, 573-1191, Japan.
Kansai Medical University · JPTokushima University · JPKyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the efficacy and safety of oral immunotherapy (OIT) combined with 24 weeks of omalizumab (OMB) at inducing desensitization in children with cow's milk allergy (CM) compared with an untreated group. The present study was a prospective randomized controlled trial. Sixteen patients (age, 6-14 years) with high IgE levels to CM were enrolled in the present study. Patients were randomized 1:1 to receive OMB-OIT group or untreated group. The primary outcome was the induction of desensitization at 8 weeks after OMB was discontinued in OMB-OIT treated group and at 32 weeks after study entry. None of the 6 children in the untreated group developed desensitization to CM while all of the 10 children in the OIT-OMB treated group achieved desensitization (P < 0.001). A significantly decreased wheal diameter in response to a skin prick test using CM was found in the OMB-OIT treated group (P < 0.05). These data suggest that OIT combined with OMB using microwave heated CM may help to induce desensitization for children with high-risk CM allergy. This prospective randomized controlled trial was intended for 50 participants but was prematurely discontinued due to overwhelming superiority of OMB combined with microwave heated OIT over CM avoidance.

Indexed as

ImmunotherapyAdministration, OralAdolescentAnimalsAnti-Allergic AgentsChildCookingDiet TherapyFemaleHumansImmunoglobulin EMaleMicrowavesMilkMilk HypersensitivityOmalizumabAnti-Allergic AgentsImmunoglobulin EOmalizumab

Identifiers

PMID29234055
PMCPMC5727171
OpenAlexW2772795169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.